Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases.

Shares of Kodiak Sciences (NASDAQ:KOD) rallied 32% Monday after Jefferies upgraded the stock to buy from hold, citing the ...

Shares of Kodiak Sciences KOD rallied 29.6% on Monday after an eminent financial services company, Jefferies, upgraded KOD to ...

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing ...

Morningstar brands and products Company Portfolio ...

Nona Biosciences announced a collaboration with Kodiak Sciences (KOD). This partnership aims to advance the discovery of ...

Nona Biosciences announced a collaboration with Kodiak Sciences (KOD). This partnership aims to advance the discovery of novel multi-target ...

Jefferies Financial Group upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning, Marketbeat.com ...

Nona Biosciences and Kodiak Sciences Partner to Advance Multi-Target Antibody Discovery for Ophthalmic Diseases ...

Tarcocimab Phase 3 trials, GLOW2 and DAYBREAK, actively enrolling for retinal diseases. Kodiak stock could reach $20 or a $1 billion+ market cap, Jefferies notes. Jefferies has upgraded Kodiak ...

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from ...